Navigation Links
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
Date:8/14/2014

BRIDGEWATER, N.J., Aug. 14, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the U.S. Food and Drug Administration (FDA) has agreed with the design of our pivotal Phase III protocol for Neutrolin® in Hemodialysis patients, and the company plans to submit the IND for Neutrolin within the next 30 days. The FDA will then have 30 days to respond to the IND.  The pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin is for use in hemodialysis patients with a central venous catheter.  The Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe.  Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program.

In addition, CorMedix is pleased to announce strategic business collaboration with Wonik Corporation, a South Korean corporation with a strong medical device franchise within the Korean healthcare market.  Wonik has a strong medical franchise and we believe it is well positioned to market, sell and distribute Neutrolin for hemodialysis patients upon receipt of regulatory approval in Korea.

Randy Milby, Chief Executive Officer of CorMedix, stated, "I am very pleased to have signed a definitive agreement with an established commercial partner, Wonik Group in South Korea, a professional and growing healthcare company in one of the key markets in East Asia.  It will of course take some time to gain regulatory approval to market the product."

"In addition, the acceptance of the Neutrolin pivotal Phase 3 clinical trial protocol is a major milestone which provide
'/>"/>

SOURCE CorMedix Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
5. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
6. KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data
7. BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
8. Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference
9. Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
10. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
11. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014 SynCardia Systems, Inc., has been recognized ... Small Companies presented by the Arizona Technology Council in ... 11th annual Governor,s Celebration of Innovation Awards honor technology ... Arizona Governor Jan Brewer ... was honored for its Freedom® portable driver, which powers ...
(Date:11/18/2014)... , Nov. 17, 2014  Nopras Technologies ... Stewart B. Rosenberg to the position ... Mr. Rosenberg joins Nopras from Bio-Investigations Ltd., a ... consultancy he founded 27 years ago, focused in ... care.  With undergraduate and graduate degrees in biology, ...
(Date:11/18/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ("Zimmer") announced ... (the "EC") to extend the deadline for the EC,s ... limited number of days in order to provide the ... extensions are not uncommon in such in-depth investigations.  Zimmer ... facilitate their review of the pending transaction and is ...
Breaking Medicine Technology:SynCardia Named Innovator of the Year by the 2014 Governor's Celebration of Innovation Awards for Its Freedom Portable Driver 2SynCardia Named Innovator of the Year by the 2014 Governor's Celebration of Innovation Awards for Its Freedom Portable Driver 3Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations 2Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations 3Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 2Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 3Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 4Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 5
(Date:11/18/2014)... MONDAY, Nov. 17, 2014 (HealthDay News) -- Women who ... increased risk for chronic, severe menstrual pain, a new ... severe menstrual pain. While smoking has been suspected as ... has been inconclusive, the authors of the new study ... taking part in a long-term study of women,s health ...
(Date:11/18/2014)... Hills, CA (PRWEB) November 18, 2014 ... and workflow solutions, announced today their Gold sponsorship of ... November 19th through Friday, November 21st at the Fargo, ... event offering targeted Microsoft Dynamics GP training sessions and ... the Microsoft campus is an excellent way for users ...
(Date:11/18/2014)... 18, 2014 Recently, Wigsbuy has introduced its ... models are offered at greatly discounted prices now, up to ... stores of human hair products, offering many real and synthetic ... the global customers, Wigsbuy uses high quality materials to make ... up with the trend. , “We are offering a ...
(Date:11/18/2014)... By Dennis Thompson ... -- Heart attack and stroke patients can safely take aspirin ... The blood-thinning combination won,t increase a patient,s risk of early ... annual meeting of the American Heart Association in Chicago. The ... Lancet . Analysis of data from more than a ...
(Date:11/17/2014)... 2014 Vernon Brewer, Founder and President of ... two weeks and saw firsthand the devastating holocaust that ISIS ... Iraq and Syria. , “‘Holocaust’ is not a term I ... or driven thousands of Christians and members of other faiths ... is desperate. As ISIS expands, they continue to kill ...
Breaking Medicine News(10 mins):Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 3Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3Health News:President of WORLD HELP Travels to Iraq and Jordan; Finds Religious Holocaust Being Executed by ISIS 2Health News:President of WORLD HELP Travels to Iraq and Jordan; Finds Religious Holocaust Being Executed by ISIS 3
... , MONDAY, March 26 (HealthDay News) -- ... preserve their fertility while undergoing cancer treatment, a new ... with cancer need more information about fertility preservation methods ... Rosen, of the University of California, San Francisco, and ...
... --Teen girls are twice as likely as boys to use ... who analyzed in-car video clips of American teen drivers, behavior. ... driving behavior for both genders, but there were a number ... by the AAA Foundation for Traffic Safety. The video ...
... Results of a study presented at the Society of ... Calif., signal a light at the end of the ... (LAPC). A new procedure called irreversible electroporation or IRE ... tumor cells around a vast and delicate network of ...
... Physicians (ACP), representing 132,000 internal medicine specialists and medical student ... (ACA) has resulted in major improvements in access and coverage ... physicians. Considering that it is just a little over two ... of its programs are not yet fully effective, the ACA ...
... Brazil, Russia, India, China and South Africa are injecting ... in the world,s poorest countries, according to a report released ... many traditional donors reduce or slow their spending, the report ... and development. While all five countries have been ...
... intervention (PCI), also known as coronary angioplasty or angioplasty, ... PCI involves opening a blocked blood vessel by threading ... a stent is also inserted to keep the blood ... usually give patients medicine to prevent complications that may ...
Cached Medicine News:Health News:Few Young Women With Cancer Take Steps to Preserve Fertility 2Health News:Teen Girl Drivers Likelier to Use Electronic Devices: Study 2Health News:Electrical pulse treatment gives pancreatic cancer patients new hope 2Health News:The present and future of the Affordable Care Act 2Health News:The present and future of the Affordable Care Act 3Health News:The present and future of the Affordable Care Act 4Health News:BRICS bringing new resources and approaches to health and development as other donors lag 2Health News:BRICS bringing new resources and approaches to health and development as other donors lag 3Health News:Complications in patients undergoing PCI tend to occur within first 30 days 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: